Veracyte, INC Form 4 insider transactions

Director Evan Jones exercised stock options and sold shares of Veracyte, Inc. under a pre-arranged 10b5-1 trading plan.

Director Evan Jones amended a previous Form 4 filing to clarify the breakdown of common stock sales executed under a Rule 10b5-1 plan.

Director Jens Holstein of Veracyte, Inc. executed sales of common stock on August 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Evan Jones exercised stock options and sold shares of Veracyte (VCYT) common stock on August 7, 2024, under a pre-arranged 10b5-1 trading plan.

Karin Eastham, a director at Veracyte, Inc., sold 7,500 shares of common stock at $25 per share on July 16, 2024, according to a Form 4 filing with the SEC.

John Leite, Chief Commercial Officer-CLIA of Veracyte, Inc., sold 1,277 shares of common stock at $25 per share on July 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Jens Holstein sold 5,000 shares of Veracyte (VCYT) common stock on July 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Evan Jones reports acquisition of restricted stock units and disposal of common stock.

Director Eliav Barr reports acquiring and disposing of Veracyte, Inc. common stock and receiving restricted stock units.

Director Jens Holstein reports acquiring and disposing of Veracyte, Inc. common stock on June 13, 2024.

Director Muna Bhanji reports acquiring and disposing of Veracyte, Inc. common stock on June 13, 2024, according to a Form 4 filing with the SEC.

Director Robert Epstein acquired 11,473 shares of Veracyte common stock and was granted restricted stock units vesting on the first anniversary or upon a change in control.

Director Karin Eastham reports acquiring and disposing of Veracyte, Inc. common stock on June 13, 2024, according to a Form 4 filing.

Karin Eastham, a director at Veracyte, Inc., sold 3,870 shares of common stock at a price of $20.59 on June 11, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Muna Bhanji sold 3,870 shares of Veracyte (VCYT) common stock at an average price of $20.3188, according to a Form 4 filing with the SEC.

Director Karin Eastham exercised stock options and sold shares of Veracyte, Inc. under a pre-arranged 10b5-1 trading plan.

Rebecca Chambers, CFO of Veracyte, reports the withholding of shares to cover tax obligations related to the vesting of restricted stock units.

Annie McGuire, SVP, General Counsel of Veracyte, Inc., reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Veracyte's CEO, Marc Stapley, reports the withholding of shares to cover tax obligations related to the vesting of Restricted Stock Units.

John Leite, Chief Commercial Officer-CLIA of Veracyte, Inc., reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Jonathan Wygant, VP and Chief Accounting Officer of Veracyte, Inc., reports the withholding of common stock to cover tax obligations related to vesting restricted stock units.

Director Muna Bhanji of Veracyte, Inc. executed a sale of 1,539 common stock shares at $21 per share on May 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Karin Eastham exercised stock options and sold 10,000 shares of Veracyte (VCYT) common stock on April 1, 2024, under a pre-arranged 10b5-1 trading plan.

Rebecca Chambers, CFO of Veracyte, Inc., reports the acquisition of 4,318 shares of common stock and the disposal of 2,189 shares to cover tax obligations.

CEO Marc Stapley reports acquisition of restricted stock units and subsequent disposal of shares to cover tax obligations.

CEO Marc Stapley reports acquiring and disposing of Veracyte common stock, including restricted stock units, according to a Form 4 filing.

John Leite, Chief Commercial Officer-CLIA of Veracyte, Inc., reports the acquisition of common stock and disposal of common stock on March 6, 2024.

Annie McGuire, SVP, General Counsel of Veracyte, Inc., reports the acquisition of restricted stock units.

Jonathan Wygant, VP and Chief Accounting Officer of Veracyte, Inc., reports acquisition and disposal of common stock and restricted stock units.

Rebecca Chambers, CFO of Veracyte, Inc., reported the acquisition of 59,856 shares of common stock and the disposal of 144,573 shares on March 6, 2024.